display
Tübingen (dpa) - The Tübingen biotech company Curevac wants to be able to use its corona vaccine from June.
The company expects both the application for approval and the approval itself in the second quarter of this year, said a spokesman for Curevac on Thursday in Tübingen.
Clinical development is in the final phase and the data for the rolling approval process by the European Medicines Agency (EMA) are expected in good time, according to the presentation of the 2020 business figures.
The corona vaccine CnCov developed by Curevac is currently being tested in an advanced phase with up to 40,000 participants.
In an additional study, it has also proven complete protection against fatal infections by virus variant B.1.351, which first appeared in South Africa, it said.
display
At the same time, the company again recorded high losses for the 2020 financial year.
Before taxes, the minus was 129.8 million euros after 100.1 million euros in 2019, as Curevac announced.
There was initially no information on earnings after taxes.
The losses are mainly due to the high costs for research and development of the corona vaccine.
In part, these have been offset by funding from the federal government, for example.
Since the summer of 2020, almost a third of the latter has also indirectly owned the company through the KfW development bank.
With the participation, Berlin wanted to secure the company against a possible takeover from abroad.
In 2020, Curevac's sales rose from EUR 17.4 million in the previous year to EUR 48.9 million.
The company justified the high increase among other things with the cooperation with the pharmaceutical company Glaxosmithkline.
Both companies cooperate in particular in the development and marketing of the next generation of the corona vaccine.
With this, Curevac would like to focus primarily on the developing virus variants.
Together with the pharmaceutical company Bayer, Curevac is working on making the first generation of the vaccine available as quickly and widely as possible.
The European Union has now secured 225 million cans and an option for 180 million more cans, said Curevac.
The company expects to produce 300 million doses of its CnCov vaccine by the end of the year and up to one billion doses in 2022.
Like the vaccines from Biontech and Moderna, Curevac's vaccine is based on what is known as “messenger RNA”.
display
© dpa-infocom, dpa: 210415-99-220311 / 2
Message